<p><strong>Pediatric use:</strong>&nbsp;Safety and effectiveness of Tenofovir in pediatric patients below the age of 18 years have not been established.<br />
<br />
<strong>Geriatrics use</strong>: Clinical studies of Tenofovir did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. But care should be taken in dose selection, and it may be useful to monitor renal function.<br />
<br />
<strong>Renal Impairment</strong>: Haemodialysis patients: 300 mg once every 7 days or after a cumulative total of 12 hr of dialysis.</p>

<ul>
	<li><strong>CrCl (10-29 mL/min)</strong>: 300 mg 72-96 hrly.</li>
	<li><strong>CrCl (30-49 mL/min)</strong>: 300 mg 48 hrly.</li>
</ul>

<p><strong>Hepatic impairment</strong>: No dose adjustment is required in patients with hepatic impairment.</p>